Targeting <scp>JAK2</scp> : Genetic and Pharmacological Inhibition Attenuates Immune‐Mediated Liver Injury by Suppressing Proinflammatory Macrophage
T cell activation. These findings collectively underscore baricitinib's therapeutic potential in modulating immune responses and restoring hepatic homeostasis in immune-mediated liver injury, positioning it as a promising therapeutic candidate for this challenging condition. Further clinical validation is warranted to translate these preclinical insights into patient care.
Authors
- Zachary Braunstein (ORCID: https://orcid.org/0000-0003-2517-9943)
- Xiaoquan Rao
- X W Li (ORCID: https://orcid.org/0000-0001-9060-1018)
- Yingying Wei
- Meijiang Zhou
- S. Lin
- C Chia-Kai Yang
- Jixin Zhong
- Jun Chen
- Quan Gong
- Xinxin Liu
Institutions
- Hubei University of Medicine (CN)
- Fujian Medical University (CN)
- Ministry of Education of the People's Republic of China (CN)
- Yangtze University (CN)
- The Ohio State University Wexner Medical Center (US)
- Fujian Institute of Microbiology (CN)
- Fujian Institute of Education (CN)
- Dongfeng General Hospital (CN)
- Tongji Hospital (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- The FASEB Journal
- Published
- 2026-04-15
- DOI
- https://doi.org/10.1096/fj.202504763rr
- Primary Topic
- Liver physiology and pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Natural Science Foundation of Hubei Province
- National Key Research and Development Program of China
- Science and Technology Program of Hubei Province